Longitudinal Immunoprofiling of the CD8 T-Cell Response in SARS-CoV-2 mRNA Vaccinees and COVID-19 Patients.

Publication date: May 22, 2025

Background: SARS-CoV-2 was the causing agent of the COVID-19 pandemic, which resulted in millions of deaths worldwide and massive economic losses. Although there are already several vaccines licensed, as novel variants develop, understanding the immune response induced by vaccination and natural infection is key for the development of future vaccines. Methods: In this study, we have used flow cytometry and next-generation sequencing to assess the longitudinal CD8 T-cell response against natural infection and vaccination in convalescent and vaccinated individuals, from early activation to immune memory establishment. Moreover, we have characterized the T-cell receptor clonality and diversity at different stages post-infection and post-vaccination. Results: We have found no significant differences in CD8 T-cell activation during the first three weeks post-infection compared to the first three weeks after first vaccination. Conversely, natural infection resulted in sustained high levels of T-cell activation at four weeks post-infection, a point in which we observed a decline in T-cell activation post-vaccination despite boosting with a second vaccination shot. Moreover, additional vaccination did not result in enhanced T-cell activation. Of note, we have observed variations in the memory subset structure at every stage of disease and vaccination. Overall, both infection and immunization induced a highly diverse T-cell receptor repertoire, which was observed both between study groups and between patients inside a given group. Conclusions: These data contribute to expand our knowledge about the immune response to SARS-CoV-2 infection and vaccination and call for additional strategies to enhance T-cell responses by booster immunization.

Open Access PDF

Concepts Keywords
Basel CD8+ T cells
Economic COVID-19
Pandemic natural infection
Vaccines SARS-CoV-2
Weeks T-cell activation
T-cell memory
TCR
vaccination

Semantics

Type Source Name
disease IDO cell
disease MESH COVID-19
disease IDO immune response
disease MESH infection
pathway REACTOME SARS-CoV-2 Infection
drug DRUGBANK Chlorhexadol
disease MESH respiratory tract infections
disease MESH Middle East respiratory syndrome
disease MESH asymptomatic infections
disease MESH viral infection
disease IDO process
disease IDO primary infection
disease MESH reinfection
drug DRUGBANK Oxygen
disease IDO blood
drug DRUGBANK Diatrizoate
drug DRUGBANK Flunarizine
drug DRUGBANK Dimethyl sulfoxide
drug DRUGBANK Nitrogen
disease MESH death
drug DRUGBANK Aspartame
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH convalescence
disease IDO history
disease IDO site
disease IDO acute infection
drug DRUGBANK Ademetionine
drug DRUGBANK Methylergometrine
disease MESH chronic infection
pathway KEGG Viral replication
disease IDO symptom
disease MESH HIV infection
pathway REACTOME HIV Infection
drug DRUGBANK Coenzyme M
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH Pneumonia
disease MESH Emergency
pathway KEGG Coronavirus disease
disease MESH Immune System Disease
drug DRUGBANK Guanosine
disease MESH breakthrough infection
disease MESH Allergy
disease MESH Hantavirus Infection
disease MESH long COVID
disease MESH Smallpox
disease MESH Yellow Fever
disease MESH myelodysplastic syndrome
disease IDO host
disease MESH tumors

Original Article

(Visited 11 times, 1 visits today)